MindWalk Holdings Corp. (NASDAQ:HYFT) Stock Has Average Target Price of $5.00 According to Brokerages

Key Points

• Analyst consensus is “Moderate Buy” among five brokerages, with an average 12-month price target of $5.00.
• MindWalk shares opened at $1.13, near the lower end of their 12-month range of $0.99 to $2.99, with a market capitalization of approximately $52.8 million.
• The company’s latest quarterly results fell short of expectations, reporting a loss of $0.09 per share versus an estimated loss of $0.05 and revenue of $2.73 million versus the $3.25 million consensus.

Shares of MindWalk Holdings Corp. (NASDAQ:HYFT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $5.00.

HYFT has been the subject of a number of recent research reports. Zacks Research upgraded shares of MindWalk from a "strong sell" rating to a "hold" rating in a research note on Monday, September 21st. HC Wainwright reaffirmed a "buy" rating on shares of MindWalk in a research report on Monday, July 20th. Weiss Ratings upgraded MindWalk from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday. Finally, Wall Street Zen upgraded MindWalk from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th.

MindWalk Stock Performance

Shares of MindWalk stock opened at $1.13 on Monday. MindWalk has a 12-month low of $0.99 and a 12-month high of $2.99. The company has a 50-day moving average of $1.34 and a two-hundred day moving average of $1.40. The stock has a market cap of $52.78 million, a PE ratio of -4.35 and a beta of 0.79. The company has a current ratio of 1.84, a quick ratio of 1.75 and a debt-to-equity ratio of 0.43.

MindWalk (NASDAQ:HYFT - Get Free Report) last issued its quarterly earnings results on Monday, September 14th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.04). MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%. The business had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.25 million. On average, research analysts anticipate that MindWalk will post -0.28 EPS for the current fiscal year.

Institutional Trading of MindWalk

An institutional investor recently bought a new stake in MindWalk stock. BlackRock Inc. bought a new position in MindWalk Holdings Corp. (NASDAQ:HYFT - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 154,411 shares of the company's stock, valued at approximately $244,000. BlackRock Inc. owned about 0.33% of MindWalk as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.70% of the company's stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.